

All-Cause Mortality and Causes of Death in the Swiss Hepatitis C Cohort Study (SCCS)

Maroussia Roelens,^{1,a} Barbara Bertisch,^{1,a} Darius Moradpour,² Andreas Cerny,³ Nasser Semmo,⁴ Patrick Schmid,⁵ Beat Müllhaupt,⁶ Olivier Clerc,⁷ David Semela,⁸ Christoph Junker,⁹ Francesco Negro,¹⁰ and Olivia Keiser¹; for the Swiss Hepatitis C Cohort Study

¹Institute of Global Health, University of Geneva, Geneva, Switzerland, ²Division of Gastroenterology and Hepatology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland, ³Fondazione Epatocentro Ticino, Lugano, Switzerland, ⁴Department for BioMedical Research, Hepatology, University of Bern, Bern, Switzerland, ⁵Division of Infectious Diseases and Hospital Epidemiology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland, ⁶Swiss Hepato-Pancreato-Biliary Center and Department of Gastroenterology and Hepatology, University Hospital, Zürich, Switzerland, ⁷Department of Internal Medicine and Infectious Diseases, Pôpital de Neuchâtel, Neuchâtel, Switzerland, ⁸Division of Gastroenterology and Hepatology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland, ⁹Swiss Federal Statistical Office, Section Population Health, Neuchâtel, Switzerland, and ¹⁰Divisions of Gastroenterology and Hepatology and of Clinical Pathology, University Hospitals Geneva, Geneva, Switzerland

Background. With direct-acting antiviral agents (DAAs), mortality rates and causes of death among persons with hepatitis C virus (HCV) infection may change over time. However, the emergence of such trends may be delayed by the slow progression of chronic hepatitis C. To date, detailed analyses of cause-specific mortality among HCV-infected persons over time remain limited.

Methods. We evaluated changes in causes of death among Swiss Hepatitis C Cohort Study (SCCS) participants from 2008 to 2016. We analyzed risk factors for all-cause and cause-specific mortality, accounting for changes in treatment, fibrosis stage, and use of injectable drugs over time. Mortality ascertainment was completed by linking lost-to-follow-up participants to the Swiss Federal Statistical Office death registry.

Results. We included 4700 SCCS participants, of whom 478 died between 2008 and 2016. The proportion of unknown causes of death decreased substantially after linkage, from 42% to 10%. Leading causes of death were liver failure (crude death rate 4.4/1000 person-years), liver cancer (3.4/1000 person-years), and nonliver cancer (2.8/1000 person-years), with an increasing proportion of cancer-related deaths over time. Cause-specific analysis showed that persons with sustained virologic response were less at risk for liver-related mortality than those never treated or treated unsuccessfully.

Conclusions. Although the expected decrease in mortality is not yet observable, causes of death among HCV-infected persons have evolved over time. With the wider use of DAAs, liver-related mortality is expected to decline in the future. Continued monitoring of cause-specific mortality will remain important to assess the long-term effect of DAAs and design effective interventions.

Keywords. cohort; hepatitis C; mortality; risk factors; Switzerland.

Hepatitis C virus (HCV) infection is a leading cause of liver-related mortality [1, 2], responsible for about 399 000 deaths worldwide in 2016. With the introduction of potent direct-acting antiviral agents (DAAs), the risk of morbidity and mortality for HCV-infected persons has decreased substantially [3]. Causes of death are likely changing over time and with age, as HCV-infected people may become increasingly at risk of dying from non-liver-related causes, including non-liver-related malignancies or cardiovascular diseases [4]. However, due to the slow natural progression of chronic hepatitis C and

the increasing number of treatments available, such trends may be slow to emerge. Some studies predict a rise in liver-related deaths to continue for another decade [5, 6]; meanwhile, the number of HCV-related deaths is stable or increasing in many settings [7].

Various studies have analyzed mortality among HCV-infected persons. In the United States, several studies have shown that HCV-related deaths disproportionately affect persons born between 1945 and 1965 [8, 9]. Both a comparison between the Chronic Hepatitis Cohort Study and the official death certificates in the United States [9] and a comparison between the Swiss Hepatitis C Cohort Study (SCCS) and the death certificates from the Swiss Federal Statistical Office (SFSO) [7] showed that under-reporting of HCV infection on death certificates is quite common. In both the United States and Switzerland, HCV-related mortality increased significantly between the late 1990s and the early 2000s, whereas HIV-related mortality decreased and hepatitis B virus (HBV)-related mortality remained relatively stable [7, 8]. In New South Wales, Australia, HCV notifications were linked to the death registry [1, 2]. When comparing mortality between HCV-infected

Received 26 February 2020; editorial decision 13 July 2020; accepted 22 July 2020.

^aEqual contribution.

Correspondence: Maroussia Roelens, PhD, Institute of Global Health, University of Geneva, Campus Biotech, Chemin des Mines 9, 1202 Geneva, Switzerland (maroussia.roelens@unige.ch).

Open Forum Infectious Diseases®

© The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (<http://creativecommons.org/licenses/by-nc-nd/4.0/>), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
DOI: 10.1093/ofid/ofaa308

persons and the general population, both liver-related and drug-related death rates were about 15–16 times higher in Australians with HCV. In HCV-mono-infected persons, liver-related deaths increased considerably with older age, and drug-related death rates were higher in younger age groups [1, 2]. In this population, liver-related mortality remained stable between 1997 and 2006, and drug-related mortality was relatively constant between 2002 and 2006 [1, 2]. More recently, a study based on the US Veterans Affairs Hepatitis C Clinical Case Registry showed that, among HCV-infected patients treated with DAAs, successful treatment substantially reduced mortality, both in the presence and absence of advanced liver disease [10, 11].

Nevertheless, few studies have analyzed detailed patterns of cause-specific mortality among HCV-infected persons [12, 13]. We therefore investigated the risk factors and time trends for all-cause and cause-specific mortality among HCV-infected persons in the SCCS. We improved mortality ascertainment by linking patients who were lost to follow-up to death certificates from the SFSO.

METHODS

The SCCS is a prospective observational cohort study, established in 2000, that continuously enrolls patients aged ≥ 18 years in Switzerland. Only persons who are confirmed to be anti-HCV antibody-positive are included [14]. Eight centers are involved, including all 5 university hospitals in Switzerland (Basel, Bern, Geneva, Lausanne, Zürich), 3 large nonuniversity hospitals (Lugano, Neuchâtel, and St. Gallen), and some affiliated centers. For all persons in the SCCS, various demographic, psychosocial, clinical, laboratory, and treatment data were collected via standardized questionnaires. The questionnaires were completed by physicians or study nurses during enrollment and at annual follow-up visits. The study was approved by all local ethics committees, and all persons provided written informed consent. For deceased persons, the cause of death was coded according to the International Statistical Classification of Diseases (ICD-10) [15]. Supplementary information was also provided to specify if the death was related to HCV infection or due to an accident, a suicide, or overdose/accidental poisoning.

We included all persons enrolled before December 31, 2016 (until when data on causes of death were compiled by the SFSO). We excluded those who died before January 1, 2008, because the new 13-digit social security number (SSN), which was needed for the linkage, became available only in 2008. Patients were lost to follow-up (LTFU) if they were not seen since August 2015 and not known to have moved abroad or to have died. Sustained virologic response (SVR) was defined as an undetectable HCV RNA ≥ 12 weeks after the end of antiviral treatment.

The SFSO has monitored causes of death in Switzerland since 1876. Causes of death are coded by ICD-10 codes based on initial, consecutive, and concomitant diseases listed on the SFSO death certificate [16]. To complete the SCCS information on

mortality, all SCCS participants who were declared LTFU or dead between January 1, 2008, and December 31, 2016, were linked to the SFSO death registry by exact record linkage. When the 13-digit SSN was available, we used it as well as the date of birth as linkage keys. If the SSN was not available, linkage was based on the dates of birth and death.

We classified the main cause of death into mutually exclusive categories as described in Table 1. The “other” category includes all causes with a frequency < 30 persons. Unnatural causes of death include suicide, overdose/accidental poisoning, and accident.

For each deceased person, we retained 1 source of information to classify the cause according to the following rules. For persons linked to the death registry, we preferentially selected ICD-10 codes from the SFSO. When this information was not available or when the SFSO provided less specific information than the SCCS, we used the ICD-10 code from the SCCS. In case no ICD-10 code was available from the SFSO or the SCCS, we used the supplementary information from the SCCS on causes of death mentioned earlier. All the deceased persons who could not be classified following this procedure were defined as “unspecified.” Finally, the cause of death classification was reviewed by an expert clinician who corrected misclassifications of complex cases specific to HCV infection.

Table 1. Categories of Causes of Death

Death Cause Group	Eligibility Criteria
Liver failure (other than liver cancer)	Selected ICD-10 codes: B15–B19 (viral hepatitis) B94.2 (sequelae of viral hepatitis) K70 (alcoholic liver disease) K71–K77 (toxic/chronic/other liver disease) T86.4 (liver transplant failure and rejection) Z94.4 (liver transplant status) OR Death identified as physically related to HCV infection according to information obtained at or after a SCCS visit
Liver cancer	Selected ICD-10 code: C22
Nonliver cancer	Selected ICD-10 codes: C00–C21, C23–C97 (all malignant neoplasms except liver cancer, including leukemia) D00–D48 (all in situ, benign, and unknown neoplasms)
Unnatural cause	Selected ICD-10 codes: S00–T88 except T86.4 (injury, poisoning, and certain other consequences of external cause) V01–Y98 (external causes of morbidity and mortality) Z92–Z99 except Z94.4 (health service-related factor) OR Death identified as due to accident, suicide, or overdose of narcotics according to the SCCS
Cardiovascular	Selected ICD-10 codes: I00–I99 (diseases of the circulatory system)
Other	All the deaths with selected ICD-10 code not entering any of the criteria described above
Unspecified	No selected ICD-10 code and no complementary information from the SCCS

Abbreviations: HCV, hepatitis C virus; ICD-10, *International Classification of Diseases, 10th revision*; SCCS, Swiss Hepatitis C Cohort Study.

For deceased persons linked to the SFSO death registry, we compared the main causes of death in the SCCS and the SFSO. We measured the interrater agreement via Kappa statistics [17] first by directly comparing the ICD-10 codes for the main cause of death and then by using the grouped causes of death (Table 1).

We calculated crude mortality rates overall and for different time periods, both for all-cause mortality and individual death cause groups. We also conducted survival analysis, for which follow-up time was calculated from enrollment into the cohort or starting date of the period of interest (baseline) to the censoring date (which was either the date of death or the last known date of being alive). When the dates of death in the SCCS and SFSO were different, we used the date from the SFSO.

We calculated crude cumulative incidences for each cause of death group, accounting for competing risk (each cause of death being a competing risk for the other causes) using the R *mstate* package [18]. We used univariable and multivariable Cox proportional hazard regression, including time-dependent covariables [18, 19], to determine risk factors of mortality. We first analyzed all-cause mortality, and then cause-specific mortality, for each of the causes of death (except for “other” and “unspecified”). Analyses were adjusted for sex, baseline age (as a continuous variable with restricted cubic splines [20]), fibrosis score (F1 to F4), history of injection drug use (IDU; ever, never), and treatment status (never treated, treated with SVR, treated without SVR). For all-cause mortality, we also accounted for the treatment history (never treated, ever treated and received DAA, ever treated but never received DAA). Due to the limited number of deceased patients who received DAAs, we could not add this covariable in the cause-specific analysis. To determine the fibrosis score, we combined information from liver biopsies, FibroScan analyses, and any reported cirrhosis during follow-up. Liver stiffness assessed by FibroScan was converted to Metavir scores (F1: <7.5 kPa; F2: ≥7.5 to <9.5 kPa; F3: ≥9.5 to <12.5 kPa; F4: ≥12.5 kPa), and reported cirrhosis

was translated into Metavir score F4. We made no assumption on the possible evolution of fibrosis over time and carried the values forward until the next measurement or until the end of the study. We used multiple imputation by chained equations (R *mice* package [21]) to impute missing values of time-dependent covariables for the multivariable analysis (see details in the Supplementary Data).

For sensitivity analysis, we recalculated multivariable Cox proportional hazard models without multiple imputation, excluding all persons with incomplete information on treatment type and outcome, fibrosis score, and history of IDU at any time over the period of interest.

RESULTS

A total of 4700 SCCS participants were followed between January 1, 2008, and December 31, 2016, with 471 of them (10%) reported to be deceased. The SSN was available for 66.0% (311 of 471) of persons, and for 30.4% (143 of 471) of persons the SSN was missing but the date of death was known. In addition, 245 of the followed persons were LTFU, and 214 (87.3%) had an SSN. Overall, 361 of the 471 deceased patients and 7 of the LTFU patients were linked to the SFSO death registry. Figure 1 summarizes the flowchart of the SCCS-SFSO linkage. Among the linked persons, the reported date of death was identical for 298 persons, was different for 54 persons (for 11, the difference was ±1 day), and was missing for 16 persons (including the 7 persons LTFU who were linked).

After linkage, the date of death was known for 474 of the 478 deceased persons and remained unknown for 4 persons. The median individual duration of follow-up (interquartile range [IQR]) was 6.5 (2.2–9.0) years. During a total of 26 114 person-years (pyrs) of follow-up, the overall mortality rate was 18.3/1000 pyrs (95% CI, 16.7–20.0).

Table 2 shows the baseline characteristics of all the included SCCS persons and of deceased persons who could or could not be linked to the death registry. Persons were mostly male (61.7%),




Figure 1. Flowchart illustrating the linkage between the Swiss Hepatitis C Cohort Study (SCCS) and the death registry of the Swiss Federal Office of Statistics (SFSO).

Table 2. Characteristics of Study Participants at Baseline and Causes of Death in the Swiss Hepatitis C Cohort Study: P Values From Kruskal-Wallis Rank-Sum Test for Continuous Variables and Chi-Square Test for Categorical Variables Are Shown

	All (n = 4700)	Death (n = 478)	Death Linked (n = 368)	Death Not Linked (n = 110)	P Value Linked, VS Not Linked
Sex					
Male	2901 (61.72)	338 (70.71)	259 (70.38)	79 (71.82)	.86
Female	1799 (38.28)	140 (29.29)	109 (29.62)	31 (28.18)	
Nationality					
Swiss	3456 (73.53)	372 (77.82)	291 (79.08)	81 (73.64)	.28
Other	1235 (26.28)	106 (22.18)	77 (20.92)	29 (26.36)	
Unknown	9 (0.19)	X	X	X	
Age at baseline, y	47.5 (40.6–55.1)	51.8 (44.5–60)	52 (45–60.1)	50.9 (43.3–57.2)	.31
Age at death census, y	53.5 (46.4–60.5)	56 (48.5–64.7)	56.3 (50.4–65.3)	53.6 (46.1–60)	.01
Time from baseline to death census, y	6.5 (2.2–9)	4 (2–6.5)	4.9 (2.9–6.8)	1.6 (0.6–3.5)	<.001
Treatment at baseline					
No	2910 (61.91)	263 (55.02)	194 (52.72)	69 (62.73)	NA
DAA (IFN-free)	33 (0.7)	X	X	X	
IFN-based	1757 (37.38)	215 (44.98)	174 (47.28)	41 (37.27)	
IDU at baseline					
Never	1780 (37.87)	182 (38.08)	142 (38.59)	40 (36.36)	.78
Ever	2578 (54.85)	263 (55.02)	201 (54.62)	62 (56.36)	
Unknown	342 (7.28)	33 (6.9)	25 (6.79)	8 (7.27)	
Fibrosis score at baseline					
F0, F1, or F2	2538 (54)	160 (33.47)	123 (33.42)	37 (33.64)	.42
F3 or F4	1261 (26.83)	229 (47.91)	185 (50.27)	44 (40)	
Unknown	901 (19.17)	89 (18.62)	60 (16.3)	29 (26.36)	
Treatment status at baseline					
Never treated	2910 (61.91)	263 (55.02)	194 (52.72)	69 (62.73)	.12
Treated with SVR	693 (14.74)	44 (9.21)	35 (9.51)	9 (8.18)	
Treated with failure	941 (20.02)	144 (30.13)	119 (32.34)	25 (22.73)	
Treated, outcome unknown	156 (3.32)	27 (5.65)	20 (5.43)	7 (6.36)	
BMI at baseline	24.1 (21.6–27.1)	24.9 (21.6–28.5)	24.8 (21.6–28.4)	25.7 (21.8–30.8)	.26
HIV coinfection at baseline					
No	3204 (68.17)	326 (68.2)	252 (68.48)	74 (67.27)	.24
Yes	258 (5.49)	51 (10.67)	35 (9.51)	16 (14.55)	
Unknown	1238 (26.34)	101 (21.13)	81 (22.01)	20 (18.18)	
Cirrhosis at baseline					
No	3259 (69.34)	213 (44.56)	165 (44.84)	48 (43.64)	.84
Yes	828 (17.62)	207 (43.31)	163 (44.29)	44 (40)	
Unknown	613 (13.04)	58 (12.13)	40 (10.87)	18 (16.36)	
Diabetes mellitus at baseline					
No	4019 (85.51)	336 (70.29)	274 (74.46)	62 (56.36)	.01
Yes	275 (5.85)	52 (10.88)	33 (8.97)	19 (17.27)	
Unknown	406 (8.64)	90 (18.83)	61 (16.58)	29 (26.36)	
Alcohol consumption at baseline					
Light	2952 (62.81)	268 (56.07)	199 (54.08)	69 (62.73)	.11
Former	348 (7.4)	43 (9)	38 (10.33)	5 (4.55)	
Heavy	749 (15.94)	111 (23.22)	91 (24.73)	20 (18.18)	
Moderate	563 (11.98)	46 (9.62)	34 (9.24)	12 (10.91)	
Unknown	88 (1.87)	10 (2.09)	6 (1.63)	4 (3.64)	
Cause of death					
Cardiovascular	33 (0.7)	33 (6.9)	26 (7.07)	7 (6.36)	NA
Liver cancer	89 (1.89)	89 (18.62)	84 (22.83)	5 (4.55)	
Liver failure	114 (2.43)	114 (23.85)	99 (26.9)	15 (13.64)	
Nonliver cancer	72 (1.53)	72 (15.06)	65 (17.66)	7 (6.36)	
Other	59 (1.26)	59 (12.34)	41 (11.14)	18 (16.36)	
Unnatural	65 (1.38)	65 (13.6)	53 (14.4)	12 (10.91)	

Abbreviations: BMI, body mass index; DAA, direct-acting antiviral agent; IDU, injection drug use; IFN, interferon; SVR, sustained virologic response; VS, versus.

Swiss nationals (73.5%), and their median age at start of follow-up (IQR) was 47.5 (40.6–55.1) years. The majority (54.9%) had a history of IDU, 38.8% had received antiviral treatment, and 17.6% were cirrhotic. Deceased persons who could or could not be linked to the death registry had similar characteristics.

Of the 368 deaths linked to the death registry, the main cause of death was available from both SCCS and SFSO for 249 persons (67.7%), and for 227 of these (91.1%) ICD-10 codes were provided in the SCCS. When comparing causes of death using ICD-10 codes, the Kappa statistic was 0.14 (40 of 227 with identical codes). If using grouped causes of death, the Kappa statistics increased to 0.45 (138 of 249 with identical causes): The agreement was weak for both approaches. A comparison of death cause groups retrieved from the SCCS and from the SFSO for persons with information on cause of death from both sources is available in the [Supplementary Data](#).

Liver failure was the leading cause of death, with a crude death rate of 4.4/1000 pyrs (95% CI, 3.6–5.2), followed by liver cancer (3.4/1000 pyrs; 95% CI, 2.8–4.2), nonliver cancer (2.8/1000 pyrs; 95% CI, 2.2–3.4), unnatural causes (2.5/1000 pyrs; 95% CI, 2.0–3.1), other causes (2.3/1000 pyrs; 95% CI, 1.8–2.9), and cardiovascular causes (1.3/1000 pyrs; 95% CI, 0.9–1.7). For 46 of the 478 deceased persons (10%), the main cause of death was unknown.

Figure 2 shows the evolution of crude mortality rates for all-cause, liver failure, and liver cancer mortality over time. Similar curves for all the cause-of-death groups listed in Table 1. Before 2014, the leading cause of death was liver failure, followed by liver cancer and nonliver cancer. In contrast, after 2014, when DAA became more widely available in Switzerland, liver cancer became the leading cause of death, followed by liver failure and nonliver cancer.

Figure 3 shows the cumulative incidence of causes of death over time. The overall probability of dying from any cause increased from 1.5% after 1 year of follow-up to 13.8% after




Figure 2. Crude mortality rates over the years for all-cause mortality, liver failure, and liver cancer mortality in the Swiss Hepatitis C Cohort Study.




Figure 3. Cumulative incidence of different causes of death since registration in the Swiss Hepatitis C cohort study (causes of death are in the same order in the legend and on the plot).

8 years. While liver failure remained the most common cause of death throughout the follow-up period, liver cancer increased in relative proportion from year 6 onwards.

Table 3 shows the risk factors from the multivariable Cox models for all-cause and cause-specific mortality in the SCCS over the period 2008–2016. Results from the univariable Cox models are presented in the [Supplementary Data](#).

For all-cause mortality, the risk of death was increased for men, older persons, those with a high fibrosis stage (hazard ratio [HR], 3.62; 95% CI, 2.92–4.49; for those with a fibrosis score \geq F3 compared with \leq F2), and those with a history of IDU (HR, 2.01; 95% CI, 1.57–2.58). Compared with persons who were never treated, the risk of death was lower for

Table 3. Estimates of the Effect of Gender, Age, Treatment, Fibrosis Stage, and IDU on Mortality, From Multivariable Cox Regression Models (A) for All-Cause Mortality and (B) for Cause-Specific Mortality

Total: 4700 Persons		All-Cause (478 Deaths)
Sex	Male	1.0 (ref)
	Female	0.68 (0.56–0.84)
Age at baseline, y	20	0.6 (0.37–0.97)
	40	1.0 (ref)
	60	2.51 (2.04–3.1)
Treatment status	Never treated	1.0 (ref)
	Treated with DAA, SVR	0.24 (0.09–0.63)
	Treated with DAA, failure	0.86 (0.27–2.75)
	Treated with IFN, SVR	0.34 (0.25–0.46)
	Treated with IFN, failure	0.86 (0.69–1.06)
Fibrosis score	F0, F1, or F2	1.0 (ref)
	F3 or F4	3.62 (2.92–4.49)
IDU	Never	1.0 (ref)
	Ever	2.01 (1.57–2.58)

Table 3. Continued

B, Cause-Specific Mortality

		Liver Failure	Liver Cancer	Nonliver Cancer	Cardiovascular	Unnatural Cause (65 Deaths, 13.6%)
Total: 4700 Persons		(114 Deaths, 23.8%)	(89 Deaths, 18.6%)	(72 Deaths, 15.1%)	(33 Deaths, 6.9%)	
Sex	Male	<i>P</i> = .17	<i>P</i> = .097	<i>P</i> = .073	<i>P</i> = .043	<i>P</i> = .18
	Female	1.0 (ref) 0.75 (0.49–1.14)	1.0 (ref) 0.67 (0.42–1.08)	1.0 (ref) 0.61 (0.36–1.05)	1.0 (ref) 0.44 (0.2–0.97)	1.0 (ref) 0.68 (0.39–1.19)
Age at baseline, y	20	<i>P</i> = .019	<i>P</i> < .001	<i>P</i> < .001	<i>P</i> < .001	<i>P</i> = .045
	40	0.27 (0.08–0.93)	0.09 (0.01–0.63)	0.05 (0.01–0.28)	0.64 (0.07–5.47)	2.9 (1.21–6.9)
	60	1.0 (ref) 2.06 (1.25–3.42)	1.0 (ref) 6.23 (2.72–14.24)	1.0 (ref) 8.34 (3.96–17.58)	1.0 (ref) 5.4 (2.13–13.72)	1.0 (ref) 1.06 (0.61–1.86)
Treatment status	Never treated	<i>P</i> < .001	<i>P</i> < .001	<i>P</i> = .27	<i>P</i> = .18	<i>P</i> = .17
	Treated with SVR	1.0 (ref)	1.0 (ref)	1.0 (ref)	1.0 (ref)	1.0 (ref)
	Treated with failure	0.18 (0.08–0.37) 0.78 (0.51–1.18)	0.33 (0.16–0.71) 1.34 (0.81–2.22)	0.59 (0.31–1.11) 0.84 (0.47–1.49)	0.42 (0.15–1.12) 0.61 (0.26–1.41)	0.5 (0.24–1.03) 0.89 (0.48–1.67)
Fibrosis score	F0, F1, or F2	<i>P</i> < .001	<i>P</i> < .001	<i>P</i> = .12	<i>P</i> = .0095	<i>P</i> = .028
	F3 or F4	1.0 (ref) 13.8 (7.69–24.75)	1.0 (ref) 14.09 (6.59–30.13)	1.0 (ref) 1.52 (0.9–2.58)	1.0 (ref) 2.81 (1.29–6.14)	1.0 (ref) 1.91 (1.07–3.4)
IDU	Never	<i>P</i> = .26	<i>P</i> = .19	<i>P</i> < .001	<i>P</i> = .17	<i>P</i> = .0011
	Ever	1.0 (ref) 1.31 (0.82–2.11)	1.0 (ref) 1.46 (0.83–2.56)	1.0 (ref) 3.22 (1.64–6.33)	1.0 (ref) 2.12 (0.73–6.18)	1.0 (ref) 3.65 (1.67–7.97)

Abbreviations: DAA, direct-acting antiviral agent; IDU, injection drug use; IFN, interferon; SVR, sustained virologic response.

treated persons who reached SVR after receiving interferon (IFN)-based treatment (HR, 0.33; 95% CI, 0.24–0.45), and even slightly lower for treated persons who reached SVR after receiving DAAs (HR, 0.23; 95% CI, 0.08–0.63). In contrast, treated persons who did not achieve SVR had a risk of death that was comparable to those who were never treated, irrespective of type of treatment.

Older persons and those with fibrosis score \geq F3 were at higher risk of dying from liver failure than younger persons and those with a fibrosis score \leq F2. Baseline treatment status was associated with mortality due to liver failure, with a pronounced protective effect for treated persons with SVR (HR, 0.18; 95% CI, 0.08–0.37) but no reduction in risk for persons treated without SVR (HR, 0.78; 95% CI, 0.51–1.18).

For liver cancer, the risk of death was higher for older persons and those with a high fibrosis stage. Having a history of IDU had little impact on liver cancer mortality. Compared with never-treated persons, the risk of dying decreased for treated persons with SVR (HR, 0.33; 95% CI, 0.16–0.71), but not for treated persons without SVR (HR, 1.34; 95% CI, 0.81–2.22).

The risk of dying from nonliver cancer was higher for older persons than for younger persons. Although there was no significant association between nonliver cancer mortality and treatment status, nor with baseline fibrosis score, persons with a history of IDU were more at risk than persons without a history of IDU (HR, 3.22; 95% CI, 1.64–6.33).

Having ever used injectable drugs was associated with an increased risk of dying from unnatural causes (HR, 3.65; 95% CI, 1.67–7.97). In addition, persons aged 20 years were more at risk than persons aged 40 years or older (HR, 2.9; 95% CI, 1.21–6.9), as well as persons with a fibrosis score \geq F3 compared with those with a fibrosis score \leq F2 (HR, 1.91; 95% CI, 1.07–3.4). There was no association between unnatural causes of death and treatment status.

Results from the sensitivity analysis were similar to the main analysis for all-cause mortality, but there were some notable differences for cause-specific mortality ([Supplementary Data](#)).

DISCUSSION

Based on SCCS data, we investigated time trends and risk factors of all-cause and cause-specific mortality among HCV-infected persons in Switzerland. Linkage of LTFU persons to the death registry did not significantly increase the number of deaths. However, the proportion of unknown causes of death decreased substantially after linkage, from 42% to 10%.

Leading causes of death changed over time, with a substantial increase in the proportion of liver cancer-related deaths. Similar to other studies [7], we found that mortality remained stable among HCV-infected persons in Switzerland over the past few years.

The risk of death was lower for women (similar to other studies [12]), younger persons, persons with a lower fibrosis

score, persons without a history of IDU, and treated persons who reached SVR, with a first indication of a more positive effect with DAAs compared with IFN-based treatments. However, in contrast to some other studies, we found little evidence that being treated with failure had a protective effect compared with remaining untreated [22, 23]. For both liver failure and liver cancer, the risk of dying was significantly associated with treatment, with a lower risk for treated persons with SVR than for treated persons without SVR or untreated persons. Having a history of IDU was an important risk factor for death from nonliver cancer and unnatural causes, explained by the inclusion of overdose/accidental poisoning in this category.

Two factors probably explain the change in leading causes of death over time: Increasing age may cause more people to die of liver disease and more people with cirrhosis to develop liver cancer; and ascertainment of cause of death may have improved over time. Indeed, the proportion of unspecified causes of death decreased from 13% in 2008–2013 to 4% in 2014–2016, reflecting the better linkage in the later years (92% of deceased persons in 2014–2016 were linked, compared with 67% in 2008–2013). Furthermore, the declining proportion of liver failure while increasing liver cancer might be due to more extensive ascertainment of small foci of hepato-cellular carcinoma (HCC) over time.

The expected decrease in mortality due to DAA is not occurring, or more probably not yet observable. Indeed, some studies have reported a decline in mortality after the introduction of DAA, but only from 2016 onwards [13]. As data for wider use of DAA were only available for 3 years (2014–2016), a period when prescription of DAA in Switzerland was limited based on fibrosis stage [24–26], we were not able to evaluate the difference between successful IFN treatment and successful DAA treatment regarding liver-related mortality.

Persons who inject drugs (PWID) are a key subgroup of HCV-infected persons in Switzerland and other high-income countries, where most HCV infections occur via IDU [27, 28].

Despite the implementation of the 4-pillar strategy [29–31], a national drug policy in Switzerland since 1994, additional obstacles exist for HCV treatment among PWID both for treatment providers and patients [32]. Consequently, some HCV-infected PWID enter care relatively late, at an advanced fibrosis stage. The proportion of infected PWID who receive anti-HCV treatments (DAA or IFN-based) has increased only slightly, from 51% in 2008–2013 to 58% in 2014–2016. The waiting time to initiate DAA treatment is likely shorter than for IFN-based treatment, and even PWID who enter care late are more likely to reach favorable outcomes with DAAs. However, persons with a history of IDU now have a higher risk of dying from nonliver cancer, potentially related to their addiction and additional risk factors common among PWID, such as smoking or excessive alcohol consumption [33].

Differences between causes of death reported in the SFSO death registry and the SCCS can be partly explained by different coding practices. The main focus of the SCCS was likely to identify all HCV-related deaths, and there was less emphasis on recording the exact cause of death. For 21% of SCCS entries, cause of death was “liver failure” in 1 data set and “liver cancer” in the other, 2 causes that are relatively similar. Overall, clear discrepancies in the causes of death recorded in the SCCS and the SFSO exist in only 21% of cases (Supplementary Data).

To our knowledge, this is one of the first studies investigating detailed risk factors and time trends of cause-specific mortality among HCV-infected persons. Via linkage with the death registry, we significantly improved information on causes of death. By accounting for competing risks, including age as a continuous covariate (and not categorizing it arbitrarily), and adjusting models for time-dependent covariables, we were able to improve the accuracy of our analysis.

A limitation of this study was the unavailability of complete data relating to fibrosis stage evolution. Hence, we made no assumption on fibrosis evolution over time and used multiple imputation to handle missing values, which may compromise the robustness of our analysis. We did a sensitivity analysis using complete cases only. In this analysis, the number of persons for the cause-specific analysis was relatively limited, and results may therefore be less reliable.

In conclusion, although mortality did not (yet) decrease with DAA, we found that causes of death changed over time. With the wider use of DAA, irrespective of fibrosis stage, liver-related mortality will likely continue to decline in the future. Continuous monitoring of mortality and causes of death will therefore remain important to the evaluation of the long-term effect of DAA and to developing effective interventions.

Supplementary Data

Supplementary materials are available at *Open Forum Infectious Diseases* online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

Acknowledgments

We gratefully thank the SCCS study nurses: Ulrike Schnee-Lach (Basel); Kathrin Husi, Alice Gilg (Bern); Nicole Eicher, Fabio Cassano (Geneva); Adeline Mathieu, Maribelle Herranz (Lausanne); Claudia Dibartolomeo (Lugano); Marielle Grosjean (Neuchâtel); Patrizia Künzler-Heule, Roman Stillhard, Michelle Grahornig, Simone Kessler (St. Gallen); Barbara Brunner-Geissmann, Andrea Zumbühl (Zürich).

We thank Danny Sheath and Rachel Esra for editorial support.

We thank the Swiss Federal Statistical Office for providing mortality data and for their support, which made this study possible.

The Swiss Hepatitis C Cohort Study group. Francesco Negro, Laurent Kaiser (Geneva); Markus Heim, Hans Hirsch (Basel); Nasser Semmo, Franziska Suter (Bern); Darius Moradpour, Vincent Aubert (Lausanne); Hans Siegrist (La Chaux-de-Fonds); Andreas Cerny, Gladys Martinetti-Lucchini (Lugano); Olivier Clerc (Neuchâtel); David Semela, Patrick

Schmid, Günter Dollenmaier (St. Gallen); Beat Müllhaupt, Elsbeth Probst-Müller (Zürich); Pascal Benkert, Thomas Fabbro, Marielle Rutquist, Constantin Sluka (Basel Clinical Trial Unit).

Financial support. This work was supported by the Swiss National Science Foundation (grant number 163878).

Potential conflicts of interest. The authors: no reported conflicts of interest. The author has submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

1. Amin J, Law MG, Bartlett M, et al. Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study. *Lancet* **2006**; 368:938–45.
2. Walter SR, Thein H-H, Amin J, et al. Trends in mortality after diagnosis of hepatitis B or C infection: 1992–2006. *J Hepatol* **2011**; 54:879–86.
3. Carrat F, Fontaine H, Dorival C, et al. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. *The Lancet* **2019**; 393(10179):1453–64.
4. Cacoub P, Nahon P, Layese R, et al; ANRS CO12 CirVir group. Prognostic value of viral eradication for major adverse cardiovascular events in hepatitis C cirrhotic patients. *Am Heart J* **2018**; 198:4–17.
5. Lee M-H, Yang H-I, Lu S-N, et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. *J Infect Dis* **2012**; 206:469–477.
6. Razavi H, Waked I, Sarrazin C, et al. The present and future burden of hepatitis C virus (HCV) infection with today's treatment paradigm. *J Viral Hepat* **2014**; 21(Suppl 1):34–59.
7. Keiser O, Giudici F, Müllhaupt B, et al; Swiss Hepatitis C Cohort Study and the Swiss National Cohort. Trends in hepatitis C-related mortality in Switzerland. *J Viral Hepat* **2018**; 25:152–60.
8. Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. *Ann Intern Med* **2012**; 156:271–8.
9. Mahajan R, Xing J, Liu SJ, et al. Mortality among persons in care with hepatitis C virus infection: the Chronic Hepatitis Cohort Study (CHecs), 2006–2010. *Clin Infect Dis* **2014**; 58:1055–1061.
10. Backus LI, Belperio PS, Shahoumian TA, Mole LA. Direct-acting antiviral sustained virologic response: impact on mortality in patients without advanced liver disease. *Hepatology* **2018**; 68:827–838.
11. Backus LI, Belperio PS, Shahoumian TA, Mole LA. Impact of sustained virologic response with direct-acting antiviral treatment on mortality in patients with advanced liver disease. *Hepatology* **2019**; 69:487–97.
12. Ireland G, Mandal S, Hickman M, Ramsay M, Harris R, Simmons R. Mortality rates among individuals diagnosed with hepatitis C virus (HCV); an observational cohort study, England, 2008 to 2016. *Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull* **2019**; 24(30):1800695.
13. Simmons R, Ireland G, Ijaz S, et al; National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Blood Borne, Sexually Transmitted Infections. Causes of death among persons diagnosed with hepatitis C infection in the pre- and post-DAA era in England: a record linkage study. *J Viral Hepat* **2019**; 26:873–80.
14. Prasad L, Spicher VM, Zwahlen M, et al; Swiss Hepatitis C Cohort Study Group. Cohort profile: the Swiss Hepatitis C Cohort Study (SCCS). *Int J Epidemiol* **2007**; 36:731–7.
15. World Health Organization (WHO). ICD-10. Version 2016. Available at: <https://icd.who.int/browse10/2016/en>. Accessed 29 November 2019.
16. Office Fédéral de la Statistique. Statistique des causes de décès en Suisse - directives concernant l'attestation médicale des causes de décès | publication. Office Fédéral de la Statistique. Published 1 December 1996. Available at: <http://content/bfs/fr/home/statistiken/kataloge-datenbanken/publikationen.assetdetail.344109.html>. Accessed 18 June 2020.
17. McHugh ML. Interrater reliability: the kappa statistic. *Biochem Med (Zagreb)* **2012**; 22:276–82.
18. Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multi-state models. *Statist Med* **2007**; 26:2389–430.
19. Fisher LD, Lin DY. Time-dependent covariates in the Cox proportional-hazards regression model. *Annu Rev Public Health* **1999**; 20:145–57.
20. Shepherd BE, Rebeiro PF. Assessing and interpreting the association between continuous covariates and outcomes in observational studies of HIV using splines. *J Acquir Immune Defic Syndr* **1999** **2017**; 74:e60–3.
21. van Buuren S, Groothuis-Oudshoorn K. Mice: multivariate imputation by chained equations in R. *J Stat Softw* **2011**; 45:1–67.
22. Dufour J-F, Bordoni A, Lorez M. Trends in hepatic cancer survival in Switzerland. *Bull Suisse Cancer* **2014**; 46–50.
23. Wen Y, Zheng YX, Tan DM. A comprehensive long-term prognosis of chronic hepatitis C patients with antiviral therapy: a meta-analysis of studies from 2008 to 2014. *Hepat Mon* **2015**; 15:e27181.
24. Lu M, Li J, Rupp LB, et al; CHecs Investigators. Hepatitis C treatment failure is associated with increased risk of hepatocellular carcinoma. *J Viral Hepat* **2016**; 23:718–29.
25. Fehr J, Moradpour D, Rauch A, Müllhaupt B. Treatment of chronic hepatitis C - September 2016 update SASL-SSI expert opinion statement. Available at: https://sasli.unibas.ch/guidelines/SASL-SSI_HepC_EOS_September_2016.pdf. Accessed 29 November 2019.
26. Vernaz N, Calmy A, Hurst S, et al. A buyers' club to improve access to hepatitis C treatment for vulnerable populations. *Swiss Med Wkly* **2018**; 148:w14649.
27. Cominetti F, Simonson T, Dubois-Arber F, Gervasoni J-P, Schaub M, Monnat M. Analyse de la situation de l'hépatite C chez les usagers de drogue en Suisse. Available at: <https://www.bag.admin.ch/dam/bag/fr/dokumente/mt/forschungsberichte/situationsanalyse-hcv-drogen.download/situationsanalyse-hcv-drogen-fr.pdf.situationsanalyse-hcv-drogen>. Accessed 3 April 2019.
28. OFSP O Fédéral de la Santé Publique. Analyse de situation des hépatites B et C en Suisse. Available at: <https://www.bag.admin.ch/bag/fr/home/das-bag/publikationen/forschungsberichte/forschungsberichte-uebertragbare-krankheiten/situationsanalyse-hepatitis.html>. Accessed 8 January 2020.
29. OFSP O Fédéral de la Santé Publique. The Swiss drug policy. Published online 2017. Available at: <https://www.bag.admin.ch/bag/en/home.html>. Accessed 30 January 2020.
30. Somaini B, Grob P. How and why AIDS changed drug policy in Switzerland. *J Public Health Policy* **2012**; 33:317–324.
31. Uchtenhagen A. Heroin-assisted treatment in Switzerland: a case study in policy change. *Addiction* **2010**; 105:29–37.
32. Negro F, Maistat L. Access to hepatitis C treatment for patients in drug substitution programmes: the fight is far from over. *Swiss Med Wkly* **2017**; 147:w14570.
33. Hudson B, Walker AJ, Irving WL. Comorbidities and medications of patients with chronic hepatitis C under specialist care in the UK. *J Med Virol* **2017**; 89:2158–64.